The triple combination therapy elexacaftor/tezacaftor/ivacaftor (ETI) has shown remarkable clinical efficacy in people with CF and at least one F508del-CFTR allele as well as a range of other CFTR mutations (Middleton et al., 2019; Heijerman et al., 2019; Burgel et al., 2024). The gene discussed is CFTR; the disease is cystic fibrosis.